Orchid Pharma QIP: ₹394.54 Cr (14 Aug 2026)
Orchid Pharma Ltd QIP monitoring report for quarter ended June 30, 2026
Orchid Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Rs. 394.54 crore QIP proceeds utilized with revised allocation approved Sept 20, 2025 AGM
- Investment of Rs. 97.62 crore in OBPL Jammu manufacturing facility, delayed, commercial ops expected Feb 2027
- Rs. 0.36 crore used for new block at Alathur API facility; entire amounts for these objects fully utilized
Why it's rated notable: the amount is 37% of annual revenue (20% to 50%)
Original filing
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Orchid Pharma
- Fundraise / allotmentOrchid Pharma Limited QIP proceeds utilization and monitoring report for Q2 FY 2026-27
- Fundraise / allotmentNotableOrchid Pharma allots 4,45,86,052 shares to Dhanuka Laboratories holders in amalgamation
- Acquisition / mergerNotableOrchid Pharma announces effective date of Scheme of Amalgamation with Dhanuka Laboratories
- Acquisition / mergerNotableOrchid Pharma Limited announces NCLT approval for merger with Dhanuka Laboratories
- Acquisition / mergerNotableOrchid Pharma Limited announces NCLT approval for amalgamation with Dhanuka Laboratories
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentUnited Heat TransferUnited Heat Transfer Limited approves half-year financial results for Sept 2026
- Fundraise / allotmentJubilant PharmovaJubilant Pharmova reports Q2 and H1 FY27 financial results and operational updates
- Fundraise / allotmentNatural CapsulesNatural Capsules Limited approves Q2 2026 results and preferential allotment
- Fundraise / allotmentNatural CapsulesNatural Capsules Ltd announces Q2 FY27 results and approves preferential allotment
- Fundraise / allotmentDestiny Logistics & InfraDestiny Logistics & Infra Ltd announces key resignations, appointments, and warrant lapse
- Fundraise / allotmentShalimar PaintsShalimar Paints Limited announces QIP Committee approval for equity shares issue
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.